132 related articles for article (PubMed ID: 35964532)
41. Nonaneurysmal Subarachnoid Hemorrhage in Sickle Cell Disease: Description of a Case and a Review of the Literature.
Zuccoli G; Nardone R; Rajan D; Khan AS; Cummings DD
Neurologist; 2018 Jul; 23(4):122-127. PubMed ID: 29953035
[TBL] [Abstract][Full Text] [Related]
42. Ethnic-Associated Phenotype Variations in Moyamoya Cerebrovascular Outcomes.
Unda SR; Antoniazzi AM; Fluss R; Yassari N; Esenwa C; Haranhalli N; Altschul DJ
Cerebrovasc Dis; 2023; 52(5):519-525. PubMed ID: 36566750
[TBL] [Abstract][Full Text] [Related]
43. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
44. Moyamoya syndrome in sickle cell anaemia: a cause of recurrent stroke.
Soares D; Bullock R; Ali S
BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25178886
[TBL] [Abstract][Full Text] [Related]
45. Risk factors for complications after abdominal surgery in children with sickle cell disease.
Snyder CW; Bludevich BM; Gonzalez R; Danielson PD; Chandler NM
J Pediatr Surg; 2021 Apr; 56(4):711-716. PubMed ID: 33010885
[TBL] [Abstract][Full Text] [Related]
46. Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke.
Adams RJ; Cox M; Ozark SD; Kanter J; Schulte PJ; Xian Y; Fonarow GC; Smith EE; Schwamm LH
Stroke; 2017 Mar; 48(3):686-691. PubMed ID: 28183857
[TBL] [Abstract][Full Text] [Related]
47. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
48. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure.
McCavit TL; Xuan L; Zhang S; Flores G; Quinn CT
Pediatr Blood Cancer; 2012 Jun; 58(6):945-9. PubMed ID: 21793185
[TBL] [Abstract][Full Text] [Related]
49. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes.
Bou-Maroun LM; Meta F; Hanba CJ; Campbell AD; Yanik GA
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28801954
[TBL] [Abstract][Full Text] [Related]
50. Thrombolytic therapy for the treatment of acute ischaemic stroke in adults with homozygous sickle cell disease.
Majhadi L; Calvet D; Rosso C; Bartolucci P
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28756377
[TBL] [Abstract][Full Text] [Related]
51. Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease.
Mucalo L; Brandow AM; Dasgupta M; Mason SF; Simpson PM; Singh A; Taylor BW; Woods KJ; Yusuf FI; Panepinto JA
Blood Adv; 2021 Jul; 5(13):2717-2724. PubMed ID: 34196678
[TBL] [Abstract][Full Text] [Related]
52. Association Between Periodic Limb Movements in Sleep and Cerebrovascular Changes in Children With Sickle Cell Disease.
Lin J; Morrone K; Manwani D; Chernin R; Silver EJ; Shifteh K; Sin S; Arens R; Graw-Panzer K
J Clin Sleep Med; 2019 Jul; 15(7):1011-1019. PubMed ID: 31383239
[TBL] [Abstract][Full Text] [Related]
53. Anesthesia for cerebral revascularization for adult moyamoya syndrome associated with sickle cell disease.
Chong CT; Manninen PH
J Clin Neurosci; 2011 Dec; 18(12):1709-12. PubMed ID: 21992742
[TBL] [Abstract][Full Text] [Related]
54. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
55. Stroke prevention by direct revascularization for patients with adult-onset moyamoya disease presenting with ischemia.
Kim T; Oh CW; Kwon OK; Hwang G; Kim JE; Kang HS; Cho WS; Bang JS
J Neurosurg; 2016 Jun; 124(6):1788-93. PubMed ID: 26636391
[TBL] [Abstract][Full Text] [Related]
56. Cerebrovascular disease in sickle cell disease.
Alakbarzade V; Maduakor C; Khan U; Khandanpour N; Rhodes E; Pereira AC
Pract Neurol; 2023 Apr; 23(2):131-138. PubMed ID: 36123118
[TBL] [Abstract][Full Text] [Related]
57. Silent cerebral infarcts in patients with sickle cell disease: a systematic review and meta-analysis.
Houwing ME; Grohssteiner RL; Dremmen MHG; Atiq F; Bramer WM; de Pagter APJ; Zwaan CM; White TJH; Vernooij MW; Cnossen MH
BMC Med; 2020 Dec; 18(1):393. PubMed ID: 33349253
[TBL] [Abstract][Full Text] [Related]
58. Oral contraceptive use and incident stroke in women with sickle cell disease.
Qureshi AI; Malik AA; Adil MM; Suri MF
Thromb Res; 2015 Aug; 136(2):315-8. PubMed ID: 26140736
[TBL] [Abstract][Full Text] [Related]
59. Ischemic infarction following an intra-cerebral hemorrhage in an adult sickle cell disease with angiographic Moyamoya.
Gupta PK; Pudukode Ramnath K; Ramadorai P; Alajmi A; Praharaju JS
J Thromb Thrombolysis; 2008 Apr; 25(2):227-30. PubMed ID: 17541764
[TBL] [Abstract][Full Text] [Related]
60. High prevalence of pro-thrombotic conditions in adult patients with moyamoya disease and moyamoya syndrome: a single center study.
Larson A; Rinaldo L; Lanzino G; Klaas JP
Acta Neurochir (Wien); 2020 Aug; 162(8):1853-1859. PubMed ID: 32462312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
